Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia

Aliaev, I.G.; Vinarov, A.Z.; Demidko, I.L.; Spivak, L.G.

Urologiia 4: 32-36

2013

ISSN/ISBN: 1728-2985
PMID: 24159762
Document Number: 15570
The article presents the results of an open, noncomparative, observational study of the efficacy and safety of continued use of the Serenoa repens (prostamol uno) plant extract at a dose of 320 mg 1 time a day for 10 years in 38 patients with early manifestations of BPH and the risk of its progression. The results of study showed the absence of progression, both on subjective criteria (IPSS, and QoL scores), and objective criteria (prostate volume, the rate of urination, residual urine volume). Furthermore, patients had no undesirable effects directly related to the use of this drug.

Document emailed within 1 workday
Secure & encrypted payments

The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia

Vinarov, A.Z.; Aliaev, I.G.; Lokshin, K.L. 2009: Safety of continuous (more than 1 year) intake of Serenoa repens extract by patients with prostatic adenoma Urologiia 1: 84; 86-87
Ibishev, K.S.; Krainy, P.A.; Mitusov, V.V.; Sizyakin, D.V.; Magomedov, G.A. 2019: A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue Urologiia 1: 40-46
Glemain, P.; Coulange, C.; Billebaud, T.; Gattegno, B.; Muszynski, R.ël.; Loeb, G.ér. 2002: Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 12(3): 395-403; Discussion 404
Vinarov, A.Z.; Aliaev, I.G.; Apolikhin, O.I.; Mazo, E.B.; Darenkov, S.P.; Demidko, I.L.; Lokshin, K.L.; Medvedev, A.A.; Permiakova, O.V.; Spivak, L.G.; Shkol'nikov, M.E. 2010: Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression Urologiia 6: 3-10
Buzelin, J.M.; Roth, S.; Geffriaud-Ricouard, C.; Delauche-Cavallier, M.C. 1997: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group European Urology 31(2): 190-198
Schneider, H.J.; Honold, E.; Masuhr, T. 1995: Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices Fortschritte der Medizin 113(3): 37-40
Palacio, A.; Hernández, C.; Marqués, A.; Prats, J.; Espinosa, F.J. 2004: Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report Archivos Espanoles de Urologia 57(4): 451-460
Bauer, H.W.; Casarosa, C.; Cosci, M.; Fratta, M.; Blessmann, G. 1999: Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study MMW Fortschritte der Medizin 141(25): 62
Tveter, K.J.; Beisland, H.O.; Andersen, J.T.; Wolf, H.; Ekman, P.; Johansson, J.E.; Kontturi, M.; Lehtonen, T. 1996: Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 116(27): 3226-3230
Kongkanand, A.; Chodchoy, V.; Lojanapiwat, B.; Pumpaisanchai, S.; Ratana-Olarn, K.; Sae-Tang, P.; Taweemonkongsap, T. 2009: Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Journal of the Medical Association of Thailand 92(7): 969-978
Adriazola Semino, M.; Lozano Ortega, J.L.; García Cobo, E.; Tejeda Báñez, E.; Romero Rodríguez, F. 1992: Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens Archivos Espanoles de Urologia 45(3): 211-213
Li, Y.-Z.; Liang, W.-N.; Zhang, G.-W.; Weng, Z.-Q.; Zhong, Y.; Xu, S.; Shang, X.-J. 2019: Efficacy and safety of lycopene in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms Zhonghua Nan Ke Xue 25(11): 1001-1004
Tarayre, J.P.; Delhon, A.; Lauressergues, H.; Stenger, A.; Barbara, M.; Bru, M.; Villanova, G.; Caillol, V.; Aliaga, M. 1983: Anti-edematous action of a hexane extract of the stone fruit of Serenoa repens Bartr Annales Pharmaceutiques Francaises 41(6): 559-570
Anwarul Islam, A.K.M.; Kashem, M.A.; Shameem, I.A.; Kibria, S.A.M.G. 2005: Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: a comparative study Bangladesh Medical Research Council Bulletin 31(2): 54-61
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Sivkov, A.V.; Egorov, A.A.; Romikh, V.V.; Surikov, V.N. 2002: Urodynamic criteria of predicting efficacy of therapy with alpha1-adrenergic blockaders in patients with benign prostatic hyperplasia Urologiia 2002(5 Suppl): 13-22
Pushkar', D.Iu.; Loran, O.B.; Petrov, S.B.; Kogan, M.I.; Zhuravlev, V.N. 2008: Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial Urologiia 2008(1): 23 25-6
Casarosa, C.; Cosci di Coscio, M.; Fratta, M. 1988: Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone Clinical Therapeutics 10(5): 585-588
Pytel', I.A.; Lopatkin, N.A.; Gorilovskiĭ, L.M.; Vinarov, A.Z.; Sivkov, A.V.; Medvedev, A.A. 2004: The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia Urologiia 2: 3-7
Wu, T.T.; Lee, Y.H.; Jiaan, B.P.; Huang, J.K. 1995: The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia Zhonghua Yi Xue Za Zhi 56(6): 399-403